Inmune Bio, Inc. (INMB) stock
INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.96+0.01 (+1.44%)
Close on Nov 17, 2026Market cap $26.64MP/E –Yield –
Inmune Bio cash
Cash and short-term investments held at the end of each period.
Inmune Bio's cash was $18.41M at Jun 30, 2026. For fiscal 2025 it was $24.75M, up 18.3% from the year before. The highest annual figure on record is $74.81M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.75M | +18.3% |
| FY2024 | Dec 31, 2024 | $20.92M | -41.6% |
| FY2023 | Dec 31, 2023 | $35.85M | -31.3% |
| FY2022 | Dec 31, 2022 | $52.15M | -30.3% |
| FY2021 | Dec 31, 2021 | $74.81M | +240.6% |
| FY2020 | Dec 31, 2020 | $21.97M | +214.0% |
| FY2019 | Dec 31, 2019 | $7.00M | +3657.2% |
| FY2018 | Dec 31, 2018 | $186.20K | -86.4% |
| FY2017 | Dec 31, 2017 | $1.37M | +867.6% |
| FY2016 | Dec 31, 2016 | $141.66K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $18.41M | -44.8% |
| Q1 FY2026 | Mar 31, 2026 | $21.36M | +10.5% |
| Q4 FY2025 | Dec 31, 2025 | $24.75M | +18.3% |
| Q3 FY2025 | Sep 30, 2025 | $27.73M | -17.3% |
| Q2 FY2025 | Jun 30, 2025 | $33.37M | +7.4% |
| Q1 FY2025 | Mar 31, 2025 | $19.34M | -25.6% |
| Q4 FY2024 | Dec 31, 2024 | $20.92M | -41.6% |
| Q3 FY2024 | Sep 30, 2024 | $33.55M | -19.8% |
| Q2 FY2024 | Jun 30, 2024 | $31.07M | -35.0% |
| Q1 FY2024 | Mar 31, 2024 | $26.00M | -49.0% |
| Q4 FY2023 | Dec 31, 2023 | $35.85M | -31.3% |
| Q3 FY2023 | Sep 30, 2023 | $41.81M | -27.2% |
| Q2 FY2023 | Jun 30, 2023 | $47.83M | -21.9% |
| Q1 FY2023 | Mar 31, 2023 | $51.00M | -23.6% |
| Q4 FY2022 | Dec 31, 2022 | $52.15M | -30.3% |
| Q3 FY2022 | Sep 30, 2022 | $57.41M | -32.0% |
| Q2 FY2022 | Jun 30, 2022 | $61.21M | +54.9% |
| Q1 FY2022 | Mar 31, 2022 | $66.73M | +47.2% |
| Q4 FY2021 | Dec 31, 2021 | $74.81M | +240.6% |
| Q3 FY2021 | Sep 30, 2021 | $84.47M | +247.5% |
| Q2 FY2021 | Jun 30, 2021 | $39.52M | +720.6% |
| Q1 FY2021 | Mar 31, 2021 | $45.34M | +664.5% |
| Q4 FY2020 | Dec 31, 2020 | $21.97M | +214.0% |
| Q3 FY2020 | Sep 30, 2020 | $24.31M | +229.3% |
| Q2 FY2020 | Jun 30, 2020 | $4.82M | -48.6% |
| Q1 FY2020 | Mar 31, 2020 | $5.93M | -1.9% |
| Q4 FY2019 | Dec 31, 2019 | $7.00M | +3657.2% |
| Q3 FY2019 | Sep 30, 2019 | $7.38M | +1034.3% |
| Q2 FY2019 | Jun 30, 2019 | $9.36M | +744.8% |
| Q1 FY2019 | Mar 31, 2019 | $6.05M | +209.2% |
| Q4 FY2018 | Dec 31, 2018 | $186.20K | -86.4% |
| Q3 FY2018 | Sep 30, 2018 | $650.86K | +359.5% |
| Q2 FY2018 | Jun 30, 2018 | $1.11M | – |
| Q1 FY2018 | Mar 31, 2018 | $1.96M | – |
| Q4 FY2017 | Dec 31, 2017 | $1.37M | – |
| Q4 FY2016 | Dec 31, 2016 | $141.66K | – |
See a number that looks wrong?